WTG
RVNC

West Tower Group’s Revance Therapeutics, Inc. RVNC Stock Holding History

West Tower Group’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,548
Closed -$39.2K – 848
2023
Q2 		$39.2K Buy
+1,548
New +$48.2K 0.03% 251

Other funds holding RVNC

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

West Tower Group's RVNC Position: Q3 2023 in Review

West Tower Group sold out of Revance Therapeutics, Inc. (RVNC) in Q3 2023, closing a stake of 1,548 shares — an estimated $39.2K sold.

West Tower Group first reported a position in RVNC in Q2 2023 and held it in 1 quarter. The position peaked at $39.2K in Q2 2023. 186 funds tracked by Wall St. Rank hold RVNC as of Q3 2023.

  • West Tower Group reported no remaining Revance Therapeutics, Inc. position as of Q3 2023 after selling out during the quarter.
  • West Tower Group sold 1,548 Revance Therapeutics, Inc. shares in Q3 2023, an estimated $39.2K.
  • West Tower Group first reported a position in Revance Therapeutics, Inc. in Q2 2023 and held it in 1 quarter.
  • West Tower Group's Revance Therapeutics, Inc. position peaked at $39.2K in Q2 2023.
  • 186 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q3 2023.

Based on West Tower Group's 13F filing for Q3 2023, filed 14 Nov 2023.